Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib as adjuvant treatment for hepatocellular carcinoma after TACE-based treatments
2010-023411-33Phase 2Terminated
- Sponsor
- Humanitas Research Hospital
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Sorafenib with Placebo (2 arms). Primary endpoints: overall survival and safety. Started Dec 2011; status: terminated.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2010-023411-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023411-33.